ClinicalTrials.gg
SuspendedNCT05832255Updated May 8, 2024

An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

A Phase 2 interventional study of Psilocybin, 1.5 mg in Fragile X Syndrome, Behavior and Cognitive Dysfunction, sponsored by Nova Mentis Life Science Corp. Suspended at 1 site in Canada. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Nova Mentis Life Science Corp · Phase 2, Interventional, and Treatment

Why this study was suspended
Indefinite hold due to protocol revisions relating to the exclusion criteria for concurrent medications.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Fragile X Syndrome with a site in Canada — 2 open to participants now, 2 under way, none of them phase 3. Fragile X Syndrome · Canada.

Planned enrollment
12th of 12
10 · median 123
Started
2023
the only one that year
Phase 2
10 of 12
2 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Nova Mentis Life Science Corp

Among the 12 studies in Fragile X Syndrome with a site in Canada, this one is the 12th largest by planned enrollment, is the only one that started in 2023, is one of 10 in phase 2, and was the 10th registered.

Fragile X Syndrome

115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.

Browse Fragile X Syndrome studies →

Open to participants now

2 of the 12 studies in Fragile X Syndrome with a site in Canada are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 18 Fragile X Syndrome studies recruiting now, 5 (28%) set no upper age limit and 13 (72%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Fragile X Syndrome with a site in Canada, or all of them as a file.
02

Study summary

Diverse symptomatology makes Fragile X Syndrome (FXS) difficult to treat, and currently there are no approved prevention or treatment methods for FXS. Current therapies, including pharmaceutical and behavioural interventions, offer a patchwork of solutions that have limited efficacy and high toxicity. The current study aims to examine psilocybin as a safe treatment alternative with the ability to improve markers of cognition, communication, mood, behavior as well as markers of neuroinflammation, serotonin levels in exosomes, and neuroplasticity at sub-hallucinogenic doses (microdosing).

The overall objective of this study is to assess the feasibility of low-dose psilocybin as a therapeutic option for individuals living with FXS and to improve diagnostic parameters of FXS, as well as therapeutic responses with the use of biomarkers.

Read the detailed description

A total of 10 subjects who meet all the inclusion criteria and does not meet any of the exclusion criteria will be enrolled into the study. Any subjects prematurely terminated from the study will be replaced to ensure 10 subjects complete the study. A study coordinator will contact referring clinicians, caregivers, and subjects to pre-screen for initial eligibility. Those deemed eligible will be invited for an in-person screening along with the participating caregiver. The screening visit will be approximately two hours long and will consist of informed consent, diagnostic interview, physical examination, drugs of abuse test (DOA), ECG, medical/treatment history review, and demographic forms. A pregnancy test will be performed on females of child-bearing during screening, baseline, and end-of-study visits. All eligible subjects will enter the treatment arm of the study.

Subjects and caregivers will return to the clinic for a baseline visit within three weeks of their screening completion. Baseline visit will include saliva/buccal swab collection, and clinician and self-report assessments for subjects and caregivers. These assessments will include the Vineland Adaptive Behavior Scales-Third Edition (VABS-3), Clinical Global Impressions-Improvement scale (CGI-I), Visual Analog Scale-Treatment Satisfaction (VAS-TS), the Anxiety, Depression and Mood Scale (ADAMS), and the Systematic Assessment For Treatment Emergent Events (SAFTEE). Digital assessments may also be performed at the baseline visit or at home at the discretion of the qualified investigator. Digital assessments will include the NIH Toolbox Cognitive Battery Modified for Intellectual Disabilities (NIH-TCB), the Trail Making Test (TMT), and the Multifaceted Empathy Test (MET).

The study drug will be dispensed in blister packs to monitor adherence and improve subject compliance. Blister packs will be prepared and distributed at each subsequent visit. Subjects will return to the clinic for study visits on day 8, 15, 22, and 28 (study end date). Subjects and caregivers will complete the assessments described above. Subjects will provide additional saliva/buccal swab samples at day 15 and day 28.

03

Conditions studied

  • Fragile X Syndrome
  • Behavior
  • Cognitive Dysfunction

Keywords

  • Fragile X Syndrome
  • Behavior
  • Cognitive Symptoms
  • Psilocybin
  • Microdose
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 50 years of age
  2. > 18.3
  3. Diagnosis of Fragile X syndrome with a molecular genetic confirmation of the full FMR1 mutation (>200 CGG repeats) or the other loss of function mutations of the FMR1 gene (SNVs and deletions of the gene) based on evidence provided by caregiver from prior assessment
  4. IQ between 40 and 85 points as reported by caregiver based on prior assessment
  5. Subject has the ability to understand and provides voluntary, written, to participate in the study

    Or,

    For subjects who are not their own legal guardian, or do not have the capacity to provide informed consent, subject's parent/legal authorized guardian is able to understand and sign an informed consent form to participate in the study.

  6. Caregiver (parent, guardian, or other legally authorized representative) who is willing to participate in the whole study and provides informed consent
  7. Subject is able to swallow tablets and capsules
  8. Individual is not of , defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been for at least 1 year prior to screening

Or,

Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

  • Abstinence (only in cases when abstinence is the usual and customary form of birth control for the participant)
  • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
  • Double-barrier method
  • Intrauterine devices
  • Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
  • Vasectomy of partner at least 6 months prior to screening

Exclusion criteria

Exclusion Criteria:

  1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
  2. Allergy, sensitivity, or intolerance to the product's active or inactive ingredients
  3. Regular use of medications that may have problematic interactions with psilocybin, including but not limited to dopamine agonists, MAO inhibitors, N-methyl-D-aspartate (NMDAR) antagonists, antipsychotics, and stimulants
  4. Urine drug test containing non-prescribed drugs of abuse (non-prescribed opioids, benzodiazepines, amphetamines, phencyclidine, cocaine) at screening and day of first treatment. Urine cannabinoid concentrations >50 ng/ml will suggest heavy marijuana use and will be a threshold for excluding potential subjects
  5. Having uncontrolled hypertension defined as an average systolic blood pressure ≥140 mmHg or an average diastolic blood pressure ≥90 mmHg, with at least 4 BP assessments completed.
  6. Have any of the following cardiovascular conditions: coronary artery disease, congenital long (time from the start of the Q wave to the end of the T wave) syndrome, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, tachycardia, artificial heart valve, a screening abnormality, or any other significant cardiovascular condition
  7. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
  8. Subjects with a history of seizure disorder except those who are currently receiving treatment with anti-epileptics and have been seizure-free for 3 months preceding screening or have been seizure-free for 3 years if not currently receiving anti-epileptics.
  9. Reported history of moderate to severe hepatic impairment
  10. Type I or insulin-dependent Type II diabetes
  11. Meet criteria for schizophrenia spectrum or other psychotic disorders, including major depressive disorder with psychotic features, or Bipolar I or Bipolar II Disorder
  12. Meet DSM-5 criteria for a moderate or severe alcohol or drug use disorder in the past 12 months
  13. Subjects who plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study
  14. Medical illness based on physical examination, ECG and routine testing that may complicate cardiovascular safety or drug metabolism or excretion, such as metabolic disease, severe cardiac disease, or kidney or liver failure as assessed by the QI. QI assessments will be based on clinical history provided by caregivers and/or physicians. Any participant requiring further assessment will be referred accordingly or excluded by the QI on a case-by-case basis.*
  15. Current or history of any significant diseases of the gastrointestinal tract, exceptions to be determined by the QI
  16. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI on a case-by-case basis
  17. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
  18. Participation in other clinical research studies 30 days prior to enrollment as assessed by the QI.
  19. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant * Blood draw to obtain laboratory samples for analysis will be avoided in this study due to the undue stress it places on this clinical population and the high safety profile of the medication at the dosage being used.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Psilocybin, 1.5 mg

    Participants will take one capsule containing 1.5 mg psilocybin with a glass of water every other day for a period of 28 days. Dosing schedule will be same for all participants with the drug taken at days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, and no treatment taken on alternating days. No subject shall be provided with more than five capsules (7.5mg psilocybin) at any one time to prevent diversion to the illicit market. If a dose is missed, participants are instructed to skip that dose and continue with their regularly scheduled medications. Participants are not to take \>1 capsule per day.

    Drug: Psilocybin, 1.5 mg

Interventions

  • Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.

06

What researchers measure

Primary outcomes

  1. Retention rate associated with 10 participants progressing to study completion.

    Study completion is defined as completing the 28-day treatment period and the final in-clinic study visit.

    Time frame: baseline to day 28

  2. Compliance with study dosing regimen as measured by the Visual Analogue Scale for Dosing (VAS-D).

    Participants will be monitored for compliance using electronic compliance checks via the remote patient reported outcomes system through recording consumption in the treatment diary. Participants and caregivers will receive daily notifications via their preferred format (i.e., email, text) during agreed upon dosage windows. Notification will include a reminder to complete a post-dosage Visual Analogue Scale for Dosing (VAS-D) to monitor for any side effects which can be submitted electronically. Failure to complete the VAS-D within the day of dosing will trigger a call from study personnel to the participant in order to do a compliance check. Study personnel will note any deviations and all points of contact with participants regarding compliance checks.

    Time frame: baseline to day 28

  3. Compliance with study dosing regimen as measured by the quantity of unused investigational product returned to the study clinic.

    Time frame: baseline to day 28

  4. Adherence with completion of diaries monitoring participant and caregiver reported outcomes.

    Adherence with study requirements for patient reported and caregiver reported outcomes (i.e., diaries) will be monitored using a remote patient reported outcomes system. Adherence will be assessed by determining the number of completed patient/caregiver diaries divided by the number of diaries expected to be completed.

    Time frame: baseline to day 28

  5. Adherence with completion of questionnaires monitoring participant and caregiver reported outcomes.

    Adherence with study requirements for patient reported and caregiver reported outcomes (i.e., questionnaires) will be monitored using a remote patient reported outcomes system. Adherence will be assessed by determining the number of completed patient/caregiver questionnaires divided by the number of questionnaires expected to be completed.

    Time frame: baseline to day 28

  6. The number of late entries for diaries monitoring patient reported and caregiver reported outcomes.

    Time frame: baseline to day 28

  7. The number of late entries for questionnaires monitoring patient reported and caregiver reported outcomes.

    Time frame: baseline to day 28

  8. Satisfaction with study questionnaire.

    Time frame: baseline to day 28

Secondary outcomes

  1. Change from baseline in standardized measures of behavioral rigidity using the ratings of repetitive and stereotyped behaviors from the revised Repetitive Behavior Scale (RBS-R).

    Time frame: baseline, day 15, day 28

  2. Change in standardized measures of empathy using the communication domain of the Vineland Adaptive Behavior Scales- Third Edition (VABS-3).

    Time frame: baseline, day 15, day 28

  3. Change in standardized measures of empathy using the overall score on the Multifaceted Empathy Test (MET).

    Time frame: baseline, day 15, day 28

  4. Change in standardized measures of expressive and receptive language skills using the communication domain of the Vineland Adaptive Behavior Scales- Third Edition (VABS-3).

    Time frame: baseline, day 15, day 28

  5. Change in standardized measures of expressive and receptive language skills using the overall score on the Multifaceted Empathy Test (MET).

    Time frame: baseline, day 15, day 28

  6. Changes in standardized measures of behavioral symptoms as measured by the Aberrant Behavior Checklist (ABC) with particular focus on ratings of repetitive/ritualistic behaviors from baseline to end of study.

    Time frame: baseline, day 8, day 15, day 21, day 28

  7. Changes in standardized measures of behavioral symptoms as measured by the Aberrant Behavior Checklist (ABC) with particular focus on ratings of aggressive behaviors from baseline to end of study.

    Time frame: baseline, day 8, day 15, day 21, day 28

  8. Changes in standardized measures of behavioral symptoms as measured by the revised Repetitive Behavior Scale (RBS-R) with particular focus on ratings of repetitive/ritualistic behaviors from baseline to end of study.

    Time frame: baseline, day 8, day 15, day 21, day 28

  9. Changes in standardized measures of behavioral symptoms as measured by the revised Repetitive Behavior Scale (RBS-R) with particular focus on ratings of aggressive behaviors from baseline to end of study.

    Time frame: baseline, day 8, day 15, day 21, day 28

  10. Changes in standardized measures of behavioral symptoms as measured by the Clinical Global Impressions (CGI) scale with particular focus on ratings of repetitive/ritualistic behaviors from baseline to end of study.

    Time frame: baseline, day 8, day 15, day 21, day 28

  11. Changes in standardized measures of behavioral symptoms as measured by the Clinical Global Impressions (CGI) scale with particular focus on ratings of aggressive behaviors from baseline to end of study.

    Time frame: baseline, day 8, day 15, day 21, day 28

  12. Changes in standardized measures of behavioral symptoms with particular focus on ratings of aggressive behaviors from baseline to end of study.

    Changes in behavioral symptoms will be measured via the Aberrant Behavior Checklist (ABC), revised Repetitive Behavior Scale (RBS-R), and Clinical Global Impressions (CGI) scale.

    Time frame: baseline, day 8, day 15, day 21, day 28

  13. Changes in overall cognition scores as measured by the NIH Toolbox Cognitive Battery Modified for Intellectual Disabilities (NIH-TCB).

    Time frame: baseline, day 28

  14. Changes in overall cognition scores as measured by the Trail Making Test (TMT)-digital version.

    Time frame: baseline, day 28

  15. Changes in overall cognition scores as measured by the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A).

    Time frame: baseline, day 28

  16. Changes in standardized measures of cognitive flexibility as measured by the NIH Toolbox Cognitive Battery Modified for Intellectual Disabilities (NIH-TCB) from baseline to end of study.

    Time frame: baseline, day 28

  17. Changes in standardized measures of cognitive flexibility as measured by the Trail Making Test (TMT)-digital version from baseline to end of study.

    Time frame: baseline, day 28

  18. Changes in standardized measures of cognitive flexibility as measured by the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) from baseline to end of study.

    Time frame: baseline, day 28

  19. Changes in standardized measures of anxiety and depression with corresponding changes in ratings of overall wellbeing.

    Changes in anxiety, depression, and overall wellbeing will be measured via the Anxiety, Depression and Mood Scale (ADAMS).

    Time frame: baseline, day 8, day 15, day 21, day 28

Other outcomes

  1. To improve diagnostic phenotyping of FXS through analysis of biomarkers using buccal swab and saliva samples.

    Machine learning algorithms will be applied to analyze and establish clustering and/or correlation between diverse datasets to help stratify adults with FSX according to subtle differences in mRNA neuroinflammatory biomarkers, serotonin signaling, and behavior.

    Time frame: baseline, day 15, day 28

  2. To characterize the role of psilocybin as a modulator of neuroinflammation through analysis of mRNA neuroinflammatory biomarkers using saliva samples from baseline to study end.

    mRNA analysis will include a panel with 52 genes including cytokines, cytokine targets, neurotransmission, serotonin signaling, membrane channel, DNA damage repair, and growth factors.

    Time frame: baseline, day 15, day 28

  3. To characterize the role of psilocybin as a modulator of neuroinflammation through analysis of mRNA neuroinflammatory biomarkers using buccal swabs from baseline to study end.

    mRNA analysis will include a panel with 52 genes including cytokines, cytokine targets, neurotransmission, serotonin signaling, membrane channel, DNA damage repair, and growth factors.

    Time frame: baseline, day 15, day 28

  4. To characterize the role of psilocybin as a modulator of neuroinflammation through analysis of serotonin levels using saliva samples from baseline to study end.

    Time frame: baseline, day 15, day 28

  5. To characterize the role of psilocybin as a modulator of neuroinflammation through analysis of serotonin levels using buccal swabs from baseline to study end.

    Time frame: baseline, day 15, day 28

  6. The incidence of pre-emergent and post-emergent adverse events.

    Time frame: baseline to 28 days

  7. The incidence of clinically significant changes in blood pressure (BP).

    Time frame: baseline, day 8, day 15, day 21, day 28

  8. The incidence of clinically significant changes in heart rate (HR).

    Time frame: baseline, day 8, day 15, day 21, day 28

07

Study locations

1 site
  • KGK Science Inc.
    London, Ontario N6B 3L1, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for May 2024, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2023
First posted
Apr 27, 2023
StartActual
Mar 28, 2023
Primary completionEst.
May 2024
CompletionEst.
May 2024
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05832255
Lead sponsor
Nova Mentis Life Science Corp
Collaborators
KGK Science Inc.
Responsible party
Sponsor
First posted
Apr 27, 2023
Start date
Mar 28, 2023
Primary completion
May 2024 (estimated)
Completion
May 2024 (estimated)
Last update
May 8, 2024

Study contacts

David Crowley, MD
principal investigator · KGK Science Inc.
Marvin Hausman, MD
study chair · Nova Mentis Life Science Corp

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion